ArticleThe oncologist2019
Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.
Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Ovarian Sertoli-Leydig cell tumors with somatic DICER1 mutations: a clinicopathologic study of 15 cases.American journal of cancer research · 2026Article
- A Rare Cause of Female Virilization: A Case Report.Cureus · 2025Article
- What is your diagnosis?Journal of the Turkish German Gynecological Association · 2025Article
- A rare case: Pure Sertoli cell tumor uncovered in atrophic ovary during postmenopausal vault prolapse evaluation.Oncoscience · 2025Article
- Current status of treatment for malignant ovarian sex cord-stromal tumors.Discover oncology · 2024Review
- Does surgery to preserve fertility in Sertoli-Leydig cell tumours increase the likelihood of spontaneous conception?BMJ case reports · 2024Article
- An Ovarian Sertoli-Leydig Cell Tumor with Elevated Alpha-Fetoprotein in an Adolescent: A Rare Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic population.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Observational
- A Sertoli-Leydig ovarian tumor presenting as ovarian torsion: A case report.Case reports in women's health · 2024Article
- Reproductive and oncologic outcomes in women with non-epithelial ovarian cancer: Single center experience over 25 years.Turkish journal of obstetrics and gynecology · 2023Article
- Ovarian Sertoli-Leydig tumor: A tricky tumor case report.International journal of surgery case reports · 2023Article
- Sertoli-Leydig cell ovarian tumour: a rare cause of virilisation and androgenic alopecia.BMJ case reports · 2022Article
- Pure Sertoli cell tumor of the ovary: A case report.Clinical case reports · 2022Article
- Distinct somatic DICER1 hotspot mutations in three metachronous ovarian Sertoli-Leydig cell tumors in a patient with DICER1 syndrome.Cancer genetics · 2022Article
- Could fertility-sparing surgery be considered for stage I ovarian sex cord-stromal tumors? A comparison of the Fine-Gray model with Cox model.Frontiers in oncology · 2022Article
- Oncological Prognosis and Fertility Outcomes of Different Surgical Extents for Malignant Ovarian Sex-Cord Stromal Tumors: A Narrative Review.Cancer management and research · 2022Review
- Characteristics and outcomes analysis of ovarian Sertoli-Leydig cell tumors (SLCTs): analysis of 15 patients.Journal of ovarian research · 2021Article
- Fertility-Sparing Surgery for Ovarian Cancer.Journal of clinical medicine · 2021Review
- Spectrum ofJournal of clinical medicine · 2021Review
- Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors.The oncologist · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSertoli-Leydig cell tumors (SLCTs) represent less than 0.5% of ovarian tumors. Because of the rarity of this tumor and its peak in frequency at around 25 years of age, this study aimed to describe SLCT management strategies.
objectiveThe objective of this study was to determine the management (i.e., conservative surgery and adjuvant chemotherapy) of ovarian SLCTs.
resultsThis retrospective analysis included 23 patients treated for ovarian SLCTs. A centralized pathologic review of the tumors was conducted. Patients were referred to or treated in our institution for an ovarian SLCT between 1994 and 2015. The median age at diagnosis was 33 years (range, 4-82 years). According to the 2014 Federation of Gynecology and Obstetrics classification, tumors were classified as stage Ia (
conclusionConservative surgery was safe for patients with stage Ia ovarian SLCTs. The place of conservative surgery for stage Ic1 remains to be defined. The best chemotherapy regimen remains to be defined. IMPLICATIONS FOR PRACTICE: For stage Ia disease, conservative surgery (in women of reproductive age) was safe and effective for treating ovarian Seroli-Leydig cell tumors. Adjuvant chemotherapy should be proposed for stage Ia when poor prognostic factors are present (poor differentiation, retiform pattern, or heterologous elements). For stage Ic1 and more severe stages, radical surgery and adjuvant chemotherapy should be considered. The combination of bleomycin, etoposide, and cisplatin was the most frequently used regimen, but the best chemotherapy regimen remains to be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.